Role of tenecteplase in ischemic stroke after 4.5 hours: an evaluation of the TRACE-III trial

Роль тенектеплазы при ишемическом инсульте после 4,5 часа: оценка исследования TRACE-III
Muhammad Adnan Zaman, Muhammad Imtiaz, Abeel Naseer, Sidra Kalsoom
2024-11-01

TRACE-III trialacute ischemic strokelarge vessel occlusionmodified Rankin scale (mRS) 0–1 at 90 daysmortality at 90 dayssymptomatic intracranial hemorrhagetenecteplase
Tenecteplase (TNK), as a thrombolytic treatment for acute ischemic stroke (AIS), has been found to be effective when used within 4.5 hours of symptom onset. However, the efficacy of TNK after 4.5 hours is not well established, especially in patients with large vessel occlusion and with no access to thrombectomy. In this article, we will discuss the results of the recently published TRACE-III trial. The study involved 516 patients with large vessel occlusion, either proximal middle cerebral artery or internal carotid artery, with salvageable brain tissue and no endovascular thrombectomy access. Key safety outcomes included symptomatic intracranial hemorrhage and death. TNK treatment resulted in a higher percentage of patients with a modified Rankin scale score of 0 or 1 at 90 days than standard medical treatment. Mortality at 90 days was 13.3% with TNK and 13.1% with standard medical treatment. The trial found that TNK treatment for Chinese patients with ischemic stroke resulted in less disability and similar survival compared to standard medical treatment. However, there was a higher incidence of symptomatic intracranial hemorrhage within 36 hours.
1
90-day mortality was similar between groups: 13.3% with TNK versus 13.1% with standard medical treatment.
2
In TRACE-III, tenecteplase (TNK) given after 4.5 hours to AIS patients with large vessel occlusion and salvageable brain tissue increased the proportion achieving mRS 0–1 at 90 days versus standard medical treatment.
3
TNK treatment resulted in less disability at 90 days for Chinese patients compared with standard medical treatment.
4
TNK was associated with a higher incidence of symptomatic intracranial hemorrhage within 36 hours compared with standard medical treatment.
5
TRACE-III focused on patients with proximal MCA or ICA large vessel occlusion who had no access to endovascular thrombectomy, addressing TNK efficacy beyond 4.5 hours in this population.

Tenecteplase treatment for acute ischemic stroke patients with large vessel occlusion and no access to endovascular thrombectomy (TRACE-III trial population)

Efficacy and safety outcomes of tenecteplase administered after 4.5 hours, including functional independence (mRS 0–1 at 90 days), mortality at 90 days, and incidence of symptomatic intracranial hemorrhage

Publication Details
Publication Date
2024-11-01
Journal
Publisher
ISSN
Cited by
1
Access Type
Author Information
Authors
Muhammad Adnan Zaman
Muhammad Imtiaz
Abeel Naseer
Sidra Kalsoom
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%